Read by QxMD icon Read


Lynne E Angus, Tali Boritz, Emily Bryntwick, Naomi Carpenter, Christianne Macaulay, Jasmine Khattra
OBJECTIVE: Recent studies suggest that it is not simply the expression of emotion or emotional arousal in session that is important, but rather it is the reflective processing of emergent, adaptive emotions, arising in the context of personal storytelling and/or Emotion-Focused Therapy (EFT) interventions, that is associated with change. METHOD: To enhance narrative-emotion integration specifically in EFT, Angus and Greenberg originally identified a set of eight clinically derived narrative-emotion integration markers were originally identified for the implementation of process-guiding therapeutic responses...
October 24, 2016: Psychotherapy Research: Journal of the Society for Psychotherapy Research
Etienne Dardenne, Himisha Beltran, Matteo Benelli, Kaitlyn Gayvert, Adeline Berger, Loredana Puca, Joanna Cyrta, Andrea Sboner, Zohal Noorzad, Theresa MacDonald, Cynthia Cheung, Ka Shing Yuen, Dong Gao, Yu Chen, Martin Eilers, Juan-Miguel Mosquera, Brian D Robinson, Olivier Elemento, Mark A Rubin, Francesca Demichelis, David S Rickman
The transition from castration-resistant prostate adenocarcinoma (CRPC) to neuroendocrine prostate cancerĀ (NEPC) has emerged as an important mechanism of treatment resistance. NEPC is associated with overexpression and gene amplification of MYCN (encoding N-Myc). N-Myc is an established oncogene in several rare pediatric tumors, but its role in prostate cancer progression is not well established. Integrating a genetically engineered mouse model and human prostate cancer transcriptome data, we show that N-Myc overexpression leads to the development of poorly differentiated, invasive prostate cancer that is molecularly similar to human NEPC...
October 10, 2016: Cancer Cell
Rebecca Kelsey
No abstract text is available yet for this article.
July 2016: Nature Reviews. Urology
Feng Sun, Zhi Wei Zhang, Ee Min Tan, Z L Ryan Lim, Yu Li, Xiao Chong Wang, Seok Eng Chua, Jun Li, Edwin Cheung, Eu-Leong Yong
Neuroendocrine prostate cancer (NEPC) has a poor prognosis, with a median survival of less than 1 year after diagnosis. Following androgen deprivation therapy, prostate adenocarcinoma cells have been observed to develop an androgen receptor-negative, terminally differentiated and indolent neuroendocrine-like phenotype. However, several molecular events, including interleukin 6 (IL-6) stimulation, in the prostate microenvironment result in the appearance of aggressive, highly proliferative castrate-resistant NEPC...
July 2016: Carcinogenesis
Meixiang Sang, Mohit Hulsurkar, Xiaochong Zhang, Haiping Song, Dayong Zheng, Yan Zhang, Min Li, Jianming Xu, Songlin Zhang, Michael Ittmann, Wenliang Li
Neuroendocrine prostate cancer (NEPC) is an aggressive subtype of prostate cancer that commonly arises through neuroendocrine differentiation (NED) of prostate adenocarcinoma (PAC) after therapy, such as radiation therapy and androgen deprivation treatment (ADT). No effective therapeutic is available for NEPC and its molecular mechanisms remain poorly understood. We have reported that G protein-coupled receptor kinase 3 (GRK3, also called ADRBK2) promotes prostate cancer progression. In this study, we demonstrate that the ADT-activated cAMP response element binding protein (CREB) directly targets and induces GRK3...
May 14, 2016: Oncotarget
Yinan Li, Nilgun Donmez, Cenk Sahinalp, Ning Xie, Yuwei Wang, Hui Xue, Fan Mo, Himisha Beltran, Martin Gleave, Yuzhuo Wang, Colin Collins, Xuesen Dong
BACKGROUND: Neuroendocrine prostate cancer (NEPC) is an aggressive subtype of castration-resistant prostate cancer that typically does not respond to androgen receptor pathway inhibition (ARPI), and its diagnosis is increasing. OBJECTIVE: To understand how NEPC develops and to identify driver genes to inform therapy for NEPC prevention. DESIGN, SETTING, AND PARTICIPANTS: Whole-transcriptome sequencing data were extracted from prostate tumors from two independent cohorts: The Beltran cohort contained 27 adenocarcinoma and five NEPC patient samples, and the Vancouver Prostate Centre cohort contained three patient samples and nine patient-derived xenografts...
May 11, 2016: European Urology
Kamlesh K Yadav, Shameer Khader, Ben Readhead, Shalini S Yadav, Li Li, Andrew Kasarksis, Ashutosh K Tewari, Joel T Dudley
BACKGROUND: Prostate cancer is the most commonly diagnosed cancer in men. More than 200,000 new cases are added each year in the US, translating to a lifetime risk of 1 in 7 men. Neuroendocrine prostate cancer (NEPC) is an aggressive and treatment-resistant form of prostate cancer. A subset of patients treated with aggressive androgen deprivation therapy (ADT) present with NEPC. Patients with NEPC have a reduced 5-year overall survival rate of 12.6%. Knowledge integration from genetic, epigenetic, biochemical and therapeutic studies suggests NEPC as an indicative mechanism of resistance development to various forms of therapy...
May 13, 2016: Current Pharmaceutical Design
H Choe, A Sboner, H Beltran, D Nanus, S T Tagawa
INTRODUCTION: Neuroendocrine prostate cancer (NEPC) is an aggressive late-stage variant of PC that is often androgen-receptor negative. Most clinicians believe the VTE rate with NEPC is higher than with standard metastatic castration-resistant PC (mCRPC), but NEPC tends to present with bulkier visceral disease and include platinum chemotherapy unlike standard PC. In many solid tumors, a more aggressive phenotype correlates with increased VTE risk and elevated expression of coagulation factors...
April 2016: Thrombosis Research
Robert W Moore, Wayne A Fritz, Andrew J Schneider, Tien-Min Lin, Amanda M Branam, Stephen Safe, Richard E Peterson
It is well established that the prototypical aryl hydrocarbon receptor (AHR) agonist 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) can both cause and protect against carcinogenesis in non-transgenic rodents. But because these animals almost never develop prostate cancer with old age or after carcinogen exposure, whether AHR activation can affect cancer of the prostate remained unknown. We used animals designed to develop this disease, Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP) mice, to investigate the potential role of AHR signaling in prostate cancer development...
August 15, 2016: Toxicology and Applied Pharmacology
Francesco Crea, Erik Venalainen, Xinpei Ci, Hongwei Cheng, Larissa Pikor, Abhijit Parolia, Hui Xue, Nur Ridzwan Nur Saidy, Dong Lin, Wan Lam, Colin Collins, Yuzhuo Wang
Neuroendocrine prostate cancer (NEPC) is the most lethal prostatic neoplasm. NEPC is thought to originate from the transdifferentiation of AR-positive adenocarcinoma cells. We have previously shown that an epigenetic/noncoding interactome (ENI) orchestrates cancer cells' plasticity, thereby allowing the emergence of metastatic, drug-resistant neoplasms. The primary objective of this manuscript is to discuss evidence indicating that some components of the ENI (Polycomb genes, miRNAs) play a key role in NEPC initiation and progression...
May 2016: Epigenomics
Tali Boritz, Ryan Barnhart, Lynne Angus, Michael J Constantino
OBJECTIVE: This study aimed to further understand how narrative flexibility contributes to therapeutic outcome in brief psychotherapy for depression utilizing the Narrative-Emotion Process Coding System (NEPCS), an observational measure that identifies specific markers of narrative and emotion integration in therapy sessions. METHOD: The present study investigated narrative flexibility by examining the contribution of NEPCS shifting (i.e., movement between NEPCS markers) in early, middle, and late sessions of client-centred therapy (CCT), emotion-focused therapy (EFT), and cognitive therapy (CT) and treatment outcome (recovered versus unchanged at the therapy termination)...
April 19, 2016: Psychotherapy Research: Journal of the Society for Psychotherapy Research
(no author information available yet)
Overexpression of MYCN in normal basal prostate cells drives formation of metastatic NEPC.
June 2016: Cancer Discovery
John K Lee, John W Phillips, Bryan A Smith, Jung Wook Park, Tanya Stoyanova, Erin F McCaffrey, Robert Baertsch, Artem Sokolov, Justin G Meyerowitz, Colleen Mathis, Donghui Cheng, Joshua M Stuart, Kevan M Shokat, W Clay Gustafson, Jiaoti Huang, Owen N Witte
MYCN amplification and overexpression are common in neuroendocrine prostate cancer (NEPC). However, the impact of aberrant N-Myc expression in prostate tumorigenesis and the cellular origin of NEPC have not been established. We define N-Myc and activated AKT1 as oncogenic components sufficient to transform human prostate epithelial cells to prostate adenocarcinoma and NEPC with phenotypic and molecular features of aggressive, late-stage human disease. We directly show that prostate adenocarcinoma and NEPC can arise from a common epithelial clone...
April 11, 2016: Cancer Cell
Himisha Beltran, Adam Jendrisak, Mark Landers, Juan Miguel Mosquera, Myriam Kossai, Jessica Louw, Rachel Krupa, Ryon P Graf, Nicole A Schreiber, David M Nanus, Scott T Tagawa, Dena Marrinucci, Ryan Dittamore, Howard I Scher
PURPOSE: The transition of prostate adenocarcinoma to a predominantly androgen receptor (AR) signaling independent phenotype can occur in the later stages of the disease and is associated with low AR expression +/- the development of small-cell or neuroendocrine tumor characteristics. As metastatic tumor biopsies are not always feasible and are difficult to repeat, we sought to evaluate noninvasive methods to identify patients transitioning toward a neuroendocrine phenotype (NEPC). EXPERIMENTAL DESIGN: We prospectively studied a metastatic tumor biopsy, serum biomarkers, and circulating tumor cells (CTC, Epic Sciences) from patients with castration-resistant prostate cancer (CRPC) including those with pure or mixed NEPC histology present on biopsy...
March 15, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
Murali Gururajan, Karen A Cavassani, Margarit Sievert, Peng Duan, Jake Lichterman, Jen-Ming Huang, Bethany Smith, Sungyong You, Srinivas Nandana, Gina Chia-Yi Chu, Sheldon Mink, Sajni Josson, Chunyan Liu, Matteo Morello, Lawrence W M Jones, Jayoung Kim, Michael R Freeman, Neil Bhowmick, Haiyen E Zhau, Leland W K Chung, Edwin M Posadas
FYN is a SRC family kinase (SFK) that has been shown to be up-regulated in human prostate cancer (PCa) tissues and cell lines. In this study, we observed that FYN is strongly up-regulated in human neuroendocrine PCa (NEPC) tissues and xenografts, as well as cells derived from a NEPC transgenic mouse model. In silico analysis of FYN expression in prostate cancer cell line databases revealed an association with the expression of neuroendocrine (NE) markers such as CHGA, CD44, CD56, and SYP. The loss of FYN abrogated the invasion of PC3 and ARCaPM cells in response to MET receptor ligand HGF...
December 29, 2015: Oncotarget
A Kretschmer, C Wittekind, C G Stief, C Gratzke
BACKGROUND: Neuroendocrine carcinoma of the prostate (NEPC) is a rare, androgen-independent variant of prostate cancer with increasing incidence of over the past few years. It commonly progresses rapidly and is associated with a poor prognosis. Based on a different tumor biology compared to adenocarcinomas of the prostate, standard therapeutic approaches for prostate cancer are ineffective. To date, no specific treatment for NEPC exists. OBJECTIVES: The purpose of this work is to provide an overview of current histopathologic characteristics, histomorphologic classifications, and current as well as future treatment options for NEPC...
December 2015: Der Urologe. Ausg. A
Kunal C Kadakia, Scott A Tomlins, Saagar K Sanghvi, Andi K Cani, Kei Omata, Daniel H Hovelson, Chia-Jen Liu, Kathleen A Cooney
IMPORTANCE: Small cell carcinoma/neuroendocrine prostate cancer (NePC) is a lethal, poorly understood prostate cancer (PCa) subtype. Controversy exists about the origin of NePC in this setting. OBJECTIVE: To molecularly profile archived biopsy specimens from a case of early-onset PCa that rapidly progressed to NePC to identify drivers of the aggressive course and mechanisms of NePC origin and progression. DESIGN, SETTING, AND PARTICIPANTS: A 47-year-old patient presented with metastatic prostatic adenocarcinoma (Gleason score 9)...
2015: Journal of Hematology & Oncology
Shusuke Akamatsu, Alexander W Wyatt, Dong Lin, Summer Lysakowski, Fan Zhang, Soojin Kim, Charan Tse, Kendric Wang, Fan Mo, Anne Haegert, Sonal Brahmbhatt, Robert Bell, Hans Adomat, Yoshihisa Kawai, Hui Xue, Xin Dong, Ladan Fazli, Harrison Tsai, Tamara L Lotan, Myriam Kossai, Juan Miguel Mosquera, Mark A Rubin, Himisha Beltran, Amina Zoubeidi, Yuzhuo Wang, Martin E Gleave, Colin C Collins
More potent targeting of the androgen receptor (AR) in advanced prostate cancer is driving an increased incidence of neuroendocrine prostate cancer (NEPC), an aggressive and treatment-resistant AR-negative variant. Its molecular pathogenesis remains poorly understood but appears to require TP53 and RB1 aberration. We modeled the development of NEPC from conventional prostatic adenocarcinoma using a patient-derived xenograft and found that the placental gene PEG10 is de-repressed during the adaptive response to AR interference and subsequently highly upregulated in clinical NEPC...
August 11, 2015: Cell Reports
Shaheen Alanee, Aaron Moore, Max Nutt, Bradley Holland, Danuta Dynda, Ahmed El-Zawahry, Kevin T McVary
AIM: The purpose of the study was to provide an update ever the incidence and mortality for neuroendocrine prostate cancer (NEPC) in the United States. PATIENTS AND METHODS: Using a large national database, we examined changes in age-adjusted incidence (AAIR), mortality rates (MR) and 5-year cancer-specific survival (CSS) for 378 patients diagnosed with NEPC between 1992 and 2011. Analysis was performed for all NEPC and for its two major sub-groups [small cell carcinoma (SCC) and neuroendocrine carcinoma (NEC)]...
July 2015: Anticancer Research
Pier-Luc Clermont, Dong Lin, Francesco Crea, Rebecca Wu, Hui Xue, Yuwei Wang, Kelsie L Thu, Wan L Lam, Colin C Collins, Yuzhuo Wang, Cheryl D Helgason
BACKGROUND: Neuroendocrine prostate cancer (NEPC) is a highly aggressive subtype of prostate cancer (PCa) for which the median survival remains less than a year. Current treatments are only palliative in nature, and the lack of suitable pre-clinical models has hampered previous efforts to develop novel therapeutic strategies. Addressing this need, we have recently established the first in vivo model of complete neuroendocrine transdifferentiation using patient-derived xenografts. Few genetic differences were observed between parental PCa and relapsed NEPC, suggesting that NEPC likely results from alterations that are epigenetic in nature...
2015: Clinical Epigenetics
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"